In this randomized phase-II study in patients with lower-risk MDS including 84% of non-del(5q) MDS, HI-E was achieved in 39 and 41% of patients receiving lenalidomide without or with ESA/G-CSF, respectively. This evidence concerns the gene CSF3 and myelodysplastic syndrome.